ClinicalTrials.Veeva

Menu

Loading Vancomycin Doses in the Emergency Department (Loaded)

Christiana Care Health Services logo

Christiana Care Health Services

Status

Completed

Conditions

Infectious Disease

Treatments

Drug: Vancomycin

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

In 2008, our ED administered an average of 245 doses of vancomycin per month. Currently there is no consistency in the ED practice in regards to vancomycin dosing. In 2009, the IDSA put forth new recommendations for vancomycin dosing in order to achieve therapeutic levels more rapidly. It has been hypothesized that if therapeutic levels are reached more rapidly then patients will in turn have better clinical outcomes and that the development of resistant organisms will be decreased. Methicillin resistant Staphylococcus aureus (MRSA) has emerged as one of the most deadly pathogens that are currently plaguing our patient population. Vancomycin is one of only a few antibiotics that are effective for treating MRSA. It is imperative that the ED physicians consistently and correctly dose vancomycin in order to give the patients the best chance to fight infection while helping to prevent further resistance in this already highly resistant organism. It is believed this study will reveal that the new dosing recommendations by the IDSA will lead to the achievement of therapeutic levels more rapidly. This information will in turn help to convince ED physicians that a change in current clinical practice is warranted and ultimately lead to better clinically outcomes for the patients.

Full description

Recently, the Infectious Disease Society of America (IDSA) has released new dosing recommendations for intravenous (IV) vancomycin. These new recommendations suggest administering an initial dose of 25-30 mg/kg of vancomycin as opposed to 10-15 mg/kg which is more traditionally done. Currently in the Emergency Department (ED) some practitioners are using the new IDSA dosing recommendations for vancomycin, while other practitioners have not changed their clinical practice. There is currently little data available to suggest that implementing these new vancomycin dosing regimens in the ED will achieve therapeutic vancomycin levels more rapidly than our traditional dosing practice.

Enrollment

99 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • At least 18 years of age
  • Treated in Christiana Emergency Department
  • Receiving Vancomycin for an infection or presumed infection
  • Being admitted to Christiana Hospital
  • Planned continued use of Vancomycin after admission.

Exclusion criteria

  • Less than 18 years of age
  • Weight greater than 120 kg.
  • Concurrent use of aminoglycosides or acyclovir
  • Sepsis patients being admitted to ICU with presumed diagnosis of pneumonia
  • Patients currently undergoing dialysis
  • Pregnant or breast feeding
  • No plan to continue Vancomycin after admission.
  • Creatinine clearance less than 50ml/min.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

99 participants in 2 patient groups

Study Drug 1
Active Comparator group
Description:
Vancomycin 15mg/kg
Treatment:
Drug: Vancomycin
Drug: Vancomycin
Study Drug 2
Active Comparator group
Description:
Vancomycin 30mg/kg
Treatment:
Drug: Vancomycin
Drug: Vancomycin

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems